Wells Fargo & Company Baudax Bio, Inc. Transaction History

Wells Fargo & Company

  • $407 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.26 - $0.87 $2 - $9
11 Added 24.44%
56 $0
Q2 2022

Aug 12, 2022
BUY
$0.68 - $1.87 $19 - $52
28 Added 164.71%
45 $0
Q1 2022

May 16, 2022
BUY
$1.58 - $8.47 $26 - $143
17 New
17 $0

About Baudax Bio, Inc.

BXRX Quotes by TradingView
  • Ticker BXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,003,700
  • Market Cap $200K
  • Description
  • Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuro...
More about BXRX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email